1. Home
  2. SPCE vs MOLN Comparison

SPCE vs MOLN Comparison

Compare SPCE & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virgin Galactic Holdings Inc.

SPCE

Virgin Galactic Holdings Inc.

HOLD

Current Price

$2.54

Market Cap

207.3M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

BUY

Current Price

$4.61

Market Cap

158.9M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
SPCE
MOLN
Founded
2017
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Transportation Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
207.3M
158.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SPCE
MOLN
Price
$2.54
$4.61
Analyst Decision
Hold
Buy
Analyst Count
6
2
Target Price
$9.22
$8.38
AVG Volume (30 Days)
4.3M
5.9K
Earning Date
02-27-2026
03-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,661,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2,528.09
$999.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$3.36
52 Week High
$6.64
$5.10

Technical Indicators

Market Signals
Indicator
SPCE
MOLN
Relative Strength Index (RSI) 38.15 60.72
Support Level $2.48 $4.33
Resistance Level $2.78 $4.74
Average True Range (ATR) 0.17 0.20
MACD -0.00 0.06
Stochastic Oscillator 26.19 86.75

Price Performance

Historical Comparison
SPCE
MOLN

About SPCE Virgin Galactic Holdings Inc.

Virgin Galactic Holdings Inc is a United States-based vertically integrated aerospace company pioneering human spaceflight for private individuals & researchers, and it also manufactures air and space vehicles. Using technologies, the company is developing a spaceflight system designed to offer its customers a multi-day, and transformative experience. This culminates in a spaceflight that includes views of Earth from space and several minutes of weightlessness that will launch from Spaceport America, New Mexico.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: